Durand J M, Cacoub P, Lunel-Fabiani F, Cosserat J, Cretel E, Kaplanski G, Frances C, Bletry O, Soubeyrand J, Godeau P
Department of Internal Medicine, CHU Sainte Marguerite, Marseille, France.
J Rheumatol. 1998 Jun;25(6):1115-7.
An open, uncontrolled trial of ribavirin, an oral guanosine nucleoside analog for treatment of hepatitis C, in patients with hepatitis C virus (HCV) associated cryoglobulinemia intolerant to interferon.
Five patients with cryoglobulinemia related to HCV infection unresponsive to interferon therapy received oral ribavirin (100 to 1200 mg daily) for 10 to 36 months.
Patients treated with ribavirin had prompt decrease in serum aminotransferase levels and marked improvement of manifestations of cryoglobulinemia within a few weeks. Ribavirin did not eradicate HCV RNA from the sera, but a decrease in viral load was observed in 3 patients, from 232 to 86 x 10(5) copies HCV/ml. Relapse occurred within 3 months once therapy was discontinued. The drug was well tolerated, but mild dose related hemolysis was common.
Ribavirin monotherapy may be effective in patients with symptomatic cryoglobulinemia related to HCV infection, but this effect is not sustained when ribavirin therapy is discontinued.
一项关于利巴韦林（一种口服鸟苷核苷类似物，用于治疗丙型肝炎）治疗对干扰素不耐受的丙型肝炎病毒（HCV）相关冷球蛋白血症患者的开放性非对照试验。
5例对干扰素治疗无反应的HCV感染相关冷球蛋白血症患者接受口服利巴韦林（每日100至1200毫克）治疗10至36个月。
接受利巴韦林治疗的患者血清转氨酶水平迅速下降，冷球蛋白血症的表现几周内明显改善。利巴韦林未从血清中清除HCV RNA，但3例患者病毒载量下降，从232降至86×10（5）拷贝HCV/毫升。一旦停药，3个月内复发。该药物耐受性良好，但轻度剂量相关溶血常见。
利巴韦林单药治疗可能对HCV感染相关有症状冷球蛋白血症患者有效，但停药后这种效果不能持续。
